CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

CVRx Inc. reported Q2 2025 revenue of $13.6 million, a 15% year-over-year increase, and narrowed its full-year guidance to $55M-$57M, reflecting the ongoing sales force transformation with 35% of territory managers hired since January. The company expanded its U.S. footprint to 240 active implanting centers and 47 sales territories, focusing on building sustainable Barostim programs. Significant positive developments in reimbursement, including CMS maintaining New Technology APC 1580 and the impending transition to Category 1 CPT codes in January 2026, are expected to eliminate experimental denials and formalize physician payments, thereby reducing adoption friction and supporting future growth.

Analysis

CVRx, Inc. reported solid Q2 2025 results with total revenue of $13.6 million, a 15% year-over-year increase, driven primarily by its U.S. Heart Failure business which grew to $12.1 million. The company expanded its commercial footprint, ending the quarter with 240 active implanting centers and 47 sales territories. However, the key operational narrative is the ongoing sales force transformation, with over 35% of territory managers hired since January 1. This has led to a narrowed full-year revenue forecast of $55 million to $57 million, reflecting the 6-to-12-month ramp-up period required for new hires to become fully productive. Management noted that the hiring phase is largely complete and focus has shifted to training and optimizing productivity. The most significant forward-looking catalyst is the impending transition to Category I CPT codes in January 2026. This development is expected to materially reduce commercial friction by eliminating automatic denials based on an "experimental" status and formalizing physician payment at approximately $550, thereby improving prior authorization predictability. This, combined with CMS's proposal to maintain the Barostim implant procedure in the high-paying New Technology APC 1580, significantly strengthens the reimbursement landscape and de-risks the company's path to wider adoption.

Key Decisions for Investors

• Investors should monitor the productivity ramp of the new sales force, as the company's ability to achieve its guidance hinges on accelerating revenue contribution from the 35% of territory managers hired since January.
• The transition to a Category I CPT code in January 2026 is a major de-risking event and potential inflection point for adoption; consider the impact of streamlined prior authorizations and predictable physician payment on future growth.
• Evaluate the company's ability to add and penetrate higher-potential Tier 1 and 2 accounts, as management has identified these as having higher utilization and being central to its refined go-to-market strategy.
• While the $95 million cash position and reduced quarterly cash burn of $8 million provide a solid runway, watch for progress updates on the proposed randomized controlled trial with the FDA, as this represents a key long-term value driver for market expansion.